SHR-A2009 wins at the PFS interim: in the global HER3 ADC vacuum, Hengrui hands in its answer sheet first

Hengrui's 2025 total revenue was RMB 31.63 billion, up 13% year on year; innovative drugs contributed RMB 16.34 billion (+26.1%, 58.3% of the total) and oncology products RMB 13.24 billion (+18.5%). Its Hong Kong IPO in May 2025 raised HK$11.4 billion (about US$1.5 billion), the largest pharma IPO in Hong Kong in five years, with proceeds explicitly directed to the ADC platform and overseas GMP upgrades. Among Chinese pharma companies, Hengrui is already the one that has all three: scale, a commercial platform and a globalization narrative.

Its commercial platform covers 25,000+ hospitals, 200,000+ retail pharmacies and 30+ provinces. The oncology business is supported by camrelizumab (PD-1, 9 indications), adebrelimab (PD-L1), apatinib (VEGFR), pyrotinib (HER2), dalpiciclib (CDK4/6), rezvilutamide (AR) and fluzoparib (PARP), and the first-line NSCLC team has cultivated respiratory and thoracic departments at major tertiary hospitals for years.

The HRMAP ADC platform has been the most active part of Hengrui's BD over the past three years. In October 2023 it signed an option with Merck KGaA on SHR-A1904 (a CLDN18.2 ADC); in December 2024 it licensed SHR-4849 (a DLL3 ADC) to IDEAYA for US$75 million upfront / US$1.045 billion total; in July 2025 it signed a platform deal with GSK covering 12 programs for US$500 million upfront + up to US$12 billion total; in September 2025 it licensed SHR-A1811 (a HER2 ADC) to Glenmark for about US$1.1 billion in potential value; and in May 2026 it struck a strategic collaboration with BMS covering 13 programs for US$600 million upfront + US$350 million in anniversary payments + US$15.2 billion total. In the past 30 months, Hengrui's ADC franchise has completed 5 deals with combined potential value exceeding US$20 billion.

SHR-A2009's position in this portfolio is special: alongside SHR-A1811 (HER2 ADC, marketed, with a breast cancer sNDA and FDA ODD in gastric cancer), it is one of the two flagships of Hengrui's ADC platform; it is one of the few among 9+ ADC molecules in development to reach Phase 3, with its Phase 3 primary endpoint positive at the May 19, 2026 interim analysis; and it is a rare high-priority molecule in Hengrui's BD history that "as of May 2026 still retains global rights and has not been licensed out on its own". After the positive interim announcement, its BD valuation anchor was instantly reset.

The official nonproprietary name is ruzaltatug rezetecan, where rezetecan is Hengrui's in-house topoisomerase I inhibitor payload system, shared with SHR-A1811 (HER2 ADC), SHR-A1921 (TROP2 ADC) and SHR-A1904 (CLDN18.2 ADC). Structurally: a fully human anti-HER3 IgG1 monoclonal antibody + a GGFG tetrapeptide cathepsin B-cleavable linker + the in-house TOP1 inhibitor 9106-IM-2, DAR=4.

This structure is almost the same class of design as patritumab deruxtecan (HER3-DXd), but both payload and antibody are developed in-house by Hengrui, avoiding Daiichi's DXd patent estate. In terms of regulatory acceptance it is the same category, while its FTO risk is significantly lower than that of third-party derivative approaches. The bystander effect is clear, giving better coverage of resistant tumors with heterogeneous HER3 expression — especially important in EGFR-TKI-resistant NSCLC: after resistance, HER3 expression positivity exceeds 83%, but expression levels are heterogeneous.

On the development path, SHR-A2009's two Phase 3 trials are very clear:

NCT06671379 / CTR20244118 (SHR-A2009-301): in patients with EGFR-mutant non-squamous NSCLC who have failed a third-generation EGFR-TKI + platinum doublet, versus investigator's choice of platinum doublet chemotherapy, N=498, primary endpoint PFS by BICR, key secondary OS. On May 19, 2026 the company announced that the PFS interim analysis had achieved a statistically significant difference; ClinicalTrials.gov still lists primary completion as December 2026 and overall completion as June 2027. This is the registration study for Hengrui's first label.

NCT07183189 (SHR-A2009-302): in 1L EGFR+ NSCLC patients, versus aumolertinib monotherapy, testing whether SHR-A2009 + aumolertinib can replace single-agent TKI in first line — a path pushing the ADC forward into the biggest gold mine, currently only in China.

In addition, NCT06092268 is a Phase 1/2 combination basket, including exploration with adebrelimab; ESMO 2023 (658MO) first reported Phase 1 solid tumor data (n=36), and ESMO 2024 (642P) reported the key EGFR+ NSCLC 9.0 mg/kg cohort (n=49). In January 2024 FDA granted Fast Track.

ESMO 2024 EGFR+ NSCLC 9.0 mg/kg cohort (n=49, median 2 prior lines, 85% resistant to third-generation TKIs, 31% with brain metastases): ORR 46.9% (23/49), DCR 93.9%, mPFS 9.6 months, median follow-up 8.6 months. No DLTs were observed across dose escalation from 1.5 to 10.5 mg/kg. At the time this was among the most closely watched later-line HER3 ADC datasets in the industry.

On May 19, 2026, Hengrui formally announced that the 301 interim analysis had met the PFS primary endpoint with statistical significance — the key leap from the single-arm effect size at ESMO 2024 to a head-to-head RCT advantage over standard of care. It must be clearly pointed out that, as of writing, quantitative results such as HR, median PFS, subgroup breakdowns and the number of interim OS events have not been published and await conference disclosure or regulatory announcement. A positive interim means that "the differentiation claim is supported by RCT evidence" has happened, but "how large the differentiation is" has not yet been quantified publicly.

On cross-study comparison, Phase 1/2 ORR of 46.9% / mPFS 9.6 months vs HER3-DXd's HERTHENA-Lung01 (5.6 mg/kg) ORR 29.8% / mPFS 5.5 months shows a clear directional gap; but HER3-DXd's real implicit signal was not ORR but OS — it first received an FDA CRL in June 2024 (for manufacturing reasons), then in May 2025 HERTHENA-Lung02 failed to achieve statistical significance on OS and the BLA was voluntarily withdrawn. The whole single-target HER3 ADC category was recalibrated at NCCN/ASCO, and KOLs began to question whether HER3 is really an independently druggable target. SHR-A2009 has now answered the first question (the PFS advantage can be reproduced in an RCT), leaving two core questions: whether OS positivity can be delivered at overall completion in June 2027, and the full picture of ILD safety.

On ILD: the ESMO 2024 abstract disclosed a drug-related ILD figure of about 8.7% (detailed grading, management and resolution curves still to be added); against the HER3-DXd HERTHENA-Lung01 baseline of any-grade ILD 5.3%, grade ≥3 1.3% and grade 5 0%, SHR-A2009's overall incidence is on the high side. Possible reasons include the higher dose (9.0 mg/kg vs 5.6 mg/kg for HER3-DXd), the lung baseline of an enrolled population with prior platinum chemotherapy, and the proportion of Asian patients with smoking history, among other factors. But whatever the cause, the 8.7% figure itself requires Hengrui to proactively provide complete Phase 3 ILD grading data for both the NDA and overseas licensing, otherwise it will become the most easily attacked safety point. On the 302 path combining with aumolertinib in 1L, the risk of ILD compounding with TKI pulmonary toxicity is also raised.

The 301 study's control arm is a platinum doublet — the CSCO 2024 NSCLC guideline Category I recommended SoC for 2L after EGFR-TKI resistance, with no ethical obstacles and design consistent internationally with HERTHENA-Lung01. BICR by RECIST 1.1 meets CDE and FDA routine requirements for PFS-primary studies. N=498 gives ample statistical power under a PFS HR assumption of 0.55–0.65, confirmed by the fact of the positive interim.

On CDE communication, the start of enrollment for CTR20244118 at the end of 2024 means the Phase 3 protocol had been accepted by CDE. After the positive interim, the company will soon submit a pre-marketing communication request to CDE. In an optimistic scenario the NDA could be submitted between H2 2026 and H1 2027, with a conditional approval window of H2 2027 to H1 2028 — but all timings are subject to formal CDE acceptance and the review pathway. FDA Fast Track was granted in January 2024, and the Type B channel on the FDA side is also open. CDE BTD has not yet been publicly listed, but the product meets the application criteria, and applying for priority review after the positive interim announcement is a reasonable move.

There is a weakness that must be acknowledged directly: 301 is a single-country Chinese design and does not meet ICH-E17 expectations for globally balanced enrollment. China's share in 301 is expected to be >70%, meaning the FDA registration path cannot rely on 301 as sole evidence; either a partner launches an ex-China MRCT, or an ex-China bridging study is done — and there is currently no public record of independent INDs in the EU/JP. The overseas pace is therefore clearly behind BL-B01D1, which already has FDA BTD and whose overseas development is led by BMS.

This is Hengrui's real leverage as a large Chinese pharma, and the core element distinguishing SHR-A2009 from a pure biotech's HER3 ADC.

The first layer of leverage is zero-increment reuse of the NSCLC sales force. Hengrui's NSCLC business already has a complete sales network supported by three products — camrelizumab, adebrelimab and apatinib — covering everything from the top 30 centers such as the Cancer Hospital of the Chinese Academy of Medical Sciences, Guangdong Provincial People's Hospital, Shanghai Chest Hospital, West China Hospital and the First Affiliated Hospital of Guangzhou Medical University, down to county-level tertiary hospitals. What SHR-A2009 needs at launch is not a new team but incremental training and medical promotion — an estimated RMB 100–200 million a year of investment is enough to take on the EGFR+ NSCLC 2L+ market. The RMB 500 million+ cost of building a commercial team from zero that a biotech faces for a single-product launch goes straight to zero at Hengrui.

The second layer of leverage is portfolio synergy. NCT06092268 is already exploring SHR-A2009 + adebrelimab (PD-L1); NCT07183189 pushes SHR-A2009 + aumolertinib into 1L EGFR+. This means Hengrui can build a complete in-house "PD-1 / PD-L1 + ADC + EGFR-TKI" matrix from first line to later lines in NSCLC — one of the few Chinese companies able to cover NSCLC, the highest-value oncology lane, end to end.

The third layer of leverage is NRDL and channels. T-DXd's NRDL listing in 2024 has opened the national negotiation path for ADCs, with reference price cuts of 60–70%; Hengrui has rich experience from years of NRDL negotiations (camrelizumab went through multiple price cuts and still held on as a leading oncology product). With 200,000+ retail pharmacies, dual-channel, DTP and internet hospitals all in place, it is especially friendly to patients like those with EGFR-TKI resistance who need 6–12 months of long-term treatment.

Stacking the three layers: China's pool of EGFR-TKI-resistant 2L+ patients grows by 130,000–150,000 a year (800,000 new NSCLC cases a year × 37.5% EGFR mutation rate × 70% first-line penetration of third-generation TKIs × 100% resistance rate, an asymmetry of more than threefold vs the 10–15% EGFR patient pool in the West). At an annual treatment cost of RMB 80,000–120,000 after negotiation × 15–25% penetration × 5-year rolling, expected peak sales from self-commercialized China rights are RMB 1.2–3.0 billion, a considerable increment to Hengrui's RMB 16.3 billion in innovative drug revenue. If the 302 path combining with aumolertinib in 1L works out, the ceiling rises further.

The key question is cannibalization risk. When SHR-A2009 expands into EGFR-WT second line, it may squeeze Hengrui's own adebrelimab + chemotherapy in the post-resistance sequencing slot in EGFR-WT. In the short term the lead EGFR+ indication is offset from the existing portfolio, but in the medium term cross-product sequencing algorithms need to be actively designed to avoid self-cannibalization within the portfolio.

The positive interim instantly pulled forward the timetable for ex-China licensing. The BD window that the market had assumed would "start negotiating after the December 2026 primary analysis" has been open since the day of the May 19, 2026 announcement, and the period up to NDA/approval is the best valuation window.

Option one is to put SHR-A2009 into BMS's May 2026 US$15.2 billion 13-program framework. BMS already holds overseas rights to BL-B01D1 (Biokin's EGFR×HER3 bispecific ADC), with which a single-target HER3 ADC directly competes; whether BMS is willing to hold two mutually substitutable assets at once is a key variable. BMS's list of 13 programs is not public, so whether SHR-A2009 is already on it is unknown. If it is, the window for a standalone single-product BD disappears; if not, the BMS framework's priority for this asset conversely proves its independence.

Option two is an independent ex-China license-out, with reference to two of Hengrui's own templates: SHR-A1811 → Glenmark (about US$1.1 billion, regional rights); SHR-4849 → IDEAYA (US$75 million upfront / US$1.045 billion total, global ex-China rights). With the current combination of a positive interim + an 8.7% ILD signal + OS data not yet in, the expected valuation anchor is US$150–250 million upfront + US$1–1.5 billion total. If complete ILD grading + positive OS can be added within 2027, bargaining power could go up another notch.

Option three is to delay ex-China BD until the OS data mature. The cost is that BL-B01D1 keeps racing ahead overseas and overseas valuations for single-target HER3 ADCs are further depressed; the benefit is that if OS data are clearly positive, it can escape the HER3-DXd disconfirmer shadow entirely and bargaining power rises substantially. This option carries significant returns and time costs alike, and the trade-off depends on the company's internal confidence in the OS data.

China rights are not among the options — the 25,000-hospital network + commercial team reuse + NRDL coverage after negotiation make the financial benefit of self-commercializing China rights far exceed China's share of any global revenue split. This is the core proposition of the commercial-platform-leverage path: don't give up China; earn license fees overseas.

Attention should be paid to co-development governance risk. Hengrui's past 5 ADC BD deals mostly followed a license-out + milestone path, and its experience with deep co-development (like the sintilimab–Lilly model) is limited. Complexity rises once the JSC/JDC governance of BMS's US$15.2 billion 13-program framework is introduced, with the risk of being crowded out by new pipeline priorities inside the partner — which is why the SHR-A1811 Glenmark model (mid-sized regional license) is relatively more robust.

China has about 800,000 new NSCLC cases a year, with an EGFR mutation rate of 37.5–40%, three times the 10–15% in the West. Third-generation TKIs (osimertinib, aumolertinib, furmonertinib) are the 1L standard; resistance develops after an mPFS of 18–20 months, adding 130,000–150,000 resistant patients a year. Later-line chemotherapy ORR is only 10–15%. This is a lane with extremely high unmet clinical need, extremely concentrated patients and an extremely strong PI network — the top 30 centers account for 60%+ of enrollment in EGFR+ NSCLC trials, and the core KOLs of the CSCO lung cancer committee (Wu Yilong, Zhou Caicun, Zhang Li, Lu Shun, etc.) are highly concentrated and work closely with Hengrui.

EGFR mutation testing penetration in Chinese tertiary hospitals exceeds 80% (30+ NMPA-approved NGS / ARMS-PCR IVD kits), and DRG single-disease payment has been incorporated. Because HER3 IHC expression after resistance exceeds 83%, the 301 design did not include mandatory CDx-based stratification, significantly reducing the commercial friction of companion diagnostics — the opposite design choice to the burden T-DXd bears of HER2 0/1+/2+/3+ stratification.

But two NSCLC-specific risk points must be acknowledged:

First, brain metastases. The brain metastasis rate in Chinese NSCLC is 30–40%, and large-molecule ADCs usually have weak CNS penetration (T-DXd being one of the few exceptions). SHR-A2009's ESMO 2023/2024 data did not separately disclose CNS subgroup results; this is both a potential differentiation gap and an opening BL-B01D1's bispecific ADC may exploit. The positive interim announcement also did not separately disclose a CNS subgroup, which needs to be filled in with later ASCO/ESMO 2026/2027 data.

Second, smoking history and lung baseline. The smoking history and smog-affected lung baseline of Chinese NSCLC patients mean a higher proportion of ILD-susceptible people, and HER3-DXd's ILD signal in Asian populations drew attention. SHR-A2009 disclosed drug-related ILD of about 8.7% at ESMO 2024, with management and resolution curves not yet clear; the RMP design needs to make ILD monitoring a core issue.

Suzhou Suncadia is Hengrui's own ADC capacity (RMB 850 million investment), already supporting clinical supply for multiple Phase 3 trials of SHR-A1811 and SHR-A2009, and an FDA inspection report was issued in January 2025 — reopening the window for regulatory dialogue. The GGFG linker + in-house rezetecan payload is the same platform system already validated by the SHR-A1811 launch, and its methods (DAR, free payload, aggregates, HCP, ADCC) have been through at least one round of CDE and FDA review and can be carried over.

But the May 2024 FDA CRL (Form 483 with eight observations) for the Lianyungang "Double-Ai" regimen (camrelizumab + apatinib) remains a public weak spot. After that event Hengrui remediated and resubmitted, but there is no public record of the Suncadia ADC facility passing an FDA pre-approval inspection, and the overseas GMP system is still being built. The Hong Kong IPO proceeds are explicitly allocated to overseas GMP upgrades — a direct company-level response to this weakness.

Another hidden risk is the process challenge of DAR=4 in the scaled-up 1L combination (302) setting. Batch volumes for the EGFR+ 1L indication are significantly larger than for 2L+, and the 9.0 mg/kg dose is high, with 30+ vials per patient per year. DAR control (a ±0.3 process window), HCP residuals (<100 ppm) and stability all need to be nailed down at the PPQ stage. No CDMO backup plan has been disclosed, a potential long-term risk point.

Viewed in the full panorama of Hengrui's 9+ ADCs in development and 5 signed BD deals, it and SHR-A1811 are the two parallel flagships. SHR-A1811 has already turned the Hengrui ADC platform narrative from "potential" to "validated by launch" (global first approval in HER2-mutant NSCLC + breast cancer sNDA accepted + FDA ODD in gastric cancer); SHR-A2009's next task is to extend this narrative from HER2 to HER3 — a lane where a global company has just withdrawn its BLA. The positive interim is a key milestone in that narrative.

Several governance judgments within the portfolio: first, resource allocation is not a constraint. 2025 innovative drug revenue was the equivalent of about US$1.634 billion (converted at the exchange rate), the Hong Kong IPO raised US$1.5 billion, and BD upfronts from BMS / GSK / Glenmark / IDEAYA and others total more than US$1.2 billion, so the RMB 300–500 million cost of the single 301 trial puts almost no pressure on company cash flow. This is the fundamental de-risking a large pharma has relative to a biotech.

Second, decision speed. Hengrui's ADC BD pace accelerated markedly in 2023–2026, with 5 licenses completed in 30 months, and its external decision-making capability is now close to that of top-tier MNCs. But public strategic statements on internal portfolio reprioritization (for example, whether to accelerate SHR-A2009's overseas path after the HER3-DXd failure) are few, and transparency of decision records remains low — a typical texture distinguishing large pharma from leading biotechs. The positive 301 interim offers a test case: over the next 60–90 days, watch whether the company advances the ex-China BD and overseas MRCT agenda at the same speed.

Third, key talent. The structure of Sun Piaoyang + Zhang Lianshan + Dai Hongbin has continued for years, and incentive tools became richer after the Hong Kong IPO. But key talent in the HRMAP ADC platform core team has not been separately disclosed; for an in-house payload system like SHR-A2009's, retention of platform technology talent is a medium-to-long-term variable.

Fourth, and most important: if SHR-A2009-301 fails to be positive on OS at overall completion, what level of event is this for the company? The answer: a short-term 5–8% hit to the H-share price, not a systemic risk. 9+ ADCs in development can hedge a single failure, and multiple BD deals — BMS US$15.2 billion + GSK US$12 billion + Glenmark US$1.1 billion + IDEAYA US$1.045 billion, among others — have already de-risked the valuation of the company's ADC platform as a whole. This is the biggest difference in strategic meaning between a large pharma holding SHR-A2009 and a biotech holding it — failure is survivable, so BD decisions can be pushed more aggressively now, with PFS positive and OS unknown.

The positive interim settled the question of "can it win on PFS", but the remaining disconfirmers are still clear. They are written out so that optimism does not mask real risks:

SHR-A2009 is an asset whose window was unexpectedly opened by an external event and which is deeply empowered by an internal commercial platform. It is not all of Hengrui, but it is the most critical test case of the whole large-pharma oncology globalization proposition: whether Hengrui's ADC platform can cross from HER2 to HER3, expand from a single marketed asset to a twin-flagship portfolio, and extend from the Chinese market to overseas licensing.

The positive interim on May 19, 2026 turned the page on "can it win on PFS", but the overall OS readout in June 2027, complete ILD grading, the timing of ex-China licensing, and the competitive pace of YL202 / BL-B01D1 are the three things that will really determine the ceiling of SHR-A2009's asset value from here.

If OS data are positive in 2027, complete ILD grading is manageable, and a quality ex-China license is completed within 2027, SHR-A2009 will become Hengrui's most valuable "retained asset" after five ADC BD deals in three years — a triple return of self-commercialized China rights + overseas license fees + a boost to the platform narrative.

If OS repeats HER3-DXd's failure, the complete ILD picture exceeds the 8.7% overall incidence disclosed at ESMO 2024, and BL-B01D1 is approved first in EGFR+ NSCLC, SHR-A2009 will still be a commercially viable asset in later-line EGFR+ NSCLC in China, but the overseas licensing and platform narrative components will be significantly compressed.

The positive interim fills the first box on the answer sheet; three more boxes remain to be written.